Oppenheimer set a $67.00 price objective on DexCom (NASDAQ:DXCM) in a research note published on Monday. The firm currently has a buy rating on the medical device company’s stock. Oppenheimer also issued estimates for DexCom’s Q4 2017 earnings at $0.07 EPS, FY2017 earnings at ($0.62) EPS, Q1 2018 earnings at ($0.32) EPS, Q2 2018 earnings at ($0.17) EPS, Q3 2018 earnings at ($0.04) EPS, Q4 2018 earnings at $0.12 EPS, FY2018 earnings at ($0.41) EPS and FY2019 earnings at ($0.06) EPS.
Several other research firms have also recently weighed in on DXCM. BidaskClub upgraded DexCom from a buy rating to a strong-buy rating in a report on Tuesday, December 12th. Zacks Investment Research cut DexCom from a hold rating to a sell rating in a report on Tuesday, October 24th. ValuEngine cut DexCom from a hold rating to a sell rating in a report on Thursday, February 8th. Barclays restated a hold rating and issued a $60.00 target price on shares of DexCom in a research note on Monday, January 8th. Finally, Northland Securities cut DexCom from a market perform rating to an under perform rating and set a $85.00 target price on the stock. in a research note on Thursday, January 4th. Three analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have issued a buy rating to the stock. The company currently has a consensus rating of Hold and an average price target of $67.44.
DexCom (NASDAQ DXCM) opened at $55.74 on Monday. DexCom has a 1-year low of $42.62 and a 1-year high of $86.32. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86.
In other news, EVP Richard Doubleday sold 1,635 shares of the company’s stock in a transaction that occurred on Friday, November 24th. The stock was sold at an average price of $55.53, for a total transaction of $90,791.55. Following the sale, the executive vice president now owns 65,049 shares in the company, valued at approximately $3,612,170.97. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Terrance H. Gregg sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $56.86, for a total value of $568,600.00. Following the sale, the insider now owns 484,559 shares in the company, valued at approximately $27,552,024.74. The disclosure for this sale can be found here. In the last quarter, insiders have sold 48,140 shares of company stock worth $2,743,281. Company insiders own 1.70% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. American International Group Inc. bought a new stake in shares of DexCom during the 4th quarter worth approximately $116,000. Advisor Group Inc. raised its stake in shares of DexCom by 104.9% during the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after purchasing an additional 837 shares in the last quarter. Thompson Davis & CO. Inc. bought a new stake in shares of DexCom during the 4th quarter worth approximately $137,000. Zions Bancorporation raised its stake in shares of DexCom by 36,222.2% during the 3rd quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock worth $160,000 after purchasing an additional 3,260 shares in the last quarter. Finally, Toronto Dominion Bank raised its stake in shares of DexCom by 251.0% during the 3rd quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock worth $178,000 after purchasing an additional 2,608 shares in the last quarter.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/02/15/oppenheimer-reiterates-67-00-price-target-for-dexcom-dxcm.html.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.